Compare Novavax Inc (NVAX) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Valero Energy Corporation — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Valero Energy Corporation trades at $433.75 (market cap $127.78B). The key difference: Valero Energy Corporation is far larger — about 70.2× Novavax Inc's market cap, and Valero Energy Corporation pays a 1.08% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Valero Energy Corporation for 56 Days on average.
| NVAX | VLO | |
|---|---|---|
Market Cap | $1.82B | $127.78B |
Volume | 6,198,505 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $12.75 | $443.80 |
52-Week Low | $6.22 | $156.39 |
Typical Hold Time | 59 Days | 56 Days |
Enterprise Value | $1.39B | $131.26B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Valero Energy (VLO) trades at $443.8, up 4.65% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Fundamentally, VLO has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $20.17 EPS. Revenue has declined from $176.4B in 2022 to $122.7B in 2025, but net income margin improved to 5.17% in 2026 projections. Analyst sentiment is predominantly positive with 54% buy ratings.
VLO's outlook is supported by refining margin strength and a solid balance sheet, but risks include potential diesel export bans and volatile energy markets. The consensus price target is $408.10, below the current price, suggesting limited near-term upside. Investors should weigh strong operational performance against macroeconomic and policy uncertainties in the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
